Last 12 months
Inside the activity.
1 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2018 Filed Aug 22, 2018 16:38 UTC |
WILLIAMS FRANK JDirector · Chief Executive Officer
|
SaleClass A Common Stock | 3,878 | $24.00 | $93,072.00 |
DisclosureSEC source: 0000950157-18-000921 · form4.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718,357 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 17, 2018 Filed Aug 20, 2018 16:37 UTC |
WILLIAMS FRANK JDirector · Chief Executive Officer
|
SaleClass A Common Stock | 7,956 | $24.00 | $190,944.00 |
DisclosureSEC source: 0000950157-18-000914 · form4.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 722,235 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 16:37 UTC |
WILLIAMS FRANK JDirector · Chief Executive Officer
|
SaleClass A Common Stock | 29,953 | $24.02 | $719,471.06 |
DisclosureSEC source: 0000950157-18-000914 · form4.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 730,191 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.00-$24.15, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 16:25 UTC |
WILLIAMS FRANK JDirector · Chief Executive Officer
|
SaleClass A Common Stock | 5,545 | $24.00 | $133,080.00 |
DisclosureSEC source: 0001628908-18-000065 · primary_doc.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 760,144 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F4 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.00-24.025, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 16:25 UTC |
WILLIAMS FRANK JDirector · Chief Executive Officer
|
SaleClass A Common Stock | 35,470 | $24.02 | $851,989.40 |
DisclosureSEC source: 0001628908-18-000065 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 765,689 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.00-$24.10, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 17:02 UTC |
WILLIAMS FRANK JDirector · Chief Executive Officer
|
SaleClass A Common Stock | 9,653 | $19.97 | $192,770.41 |
DisclosureSEC source: 0001628908-18-000059 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 801,159 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighed average. These shares were sold in multiple transactions at prices ranging from $19.60-$20.40, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 21:15 UTC |
Peterson Thomas IIIChief Executive Officer
|
SaleClass A Common Stock | 10,000 | $19.96 | $199,600.00 |
DisclosureSEC source: 0001628908-18-000060 · primary_doc.xml · nonDerivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,868 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $19.60-$20.40, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 21:28 UTC |
Blackley SethDirector · President
|
Exercise / conversionClass A Common Option (Right to Buy) · Derivative | 31,554 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-18-000058 · primary_doc.xml · derivative · entry 4 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,040 Underlying: Class A Common Stock · 31,554 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F5 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2015. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 21:28 UTC |
Blackley SethDirector · President
|
SaleClass A Common Stock | 31,554 | $22.74 | $717,537.96 |
DisclosureSEC source: 0001628908-18-000058 · primary_doc.xml · nonDerivative · entry 3 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,227 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F4 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $22.55-$23.00, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 21:28 UTC |
Blackley SethDirector · President
|
Exercise / conversionClass A Common Stock | 31,554 | $3.84 | $121,167.36 |
DisclosureSEC source: 0001628908-18-000058 · primary_doc.xml · nonDerivative · entry 2 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 21:28 UTC |
Blackley SethDirector · President
|
SaleClass A Common Stock | 20,610 | $22.72 | $468,259.20 |
DisclosureSEC source: 0001628908-18-000058 · primary_doc.xml · nonDerivative · entry 1 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,227 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $22.55-$23.00, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 05, 2018 Filed Jul 6, 2018 20:29 UTC |
Blackley SethDirector · President
|
Exercise / conversionClass A Common Option (Right to Buy) · Derivative | 32,643 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-18-000057 · primary_doc.xml · derivative · entry 8 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,594 Underlying: Class A Common Stock · 32,643 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F8 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014 and December 1, 2015. Read SEC document |
| July 05, 2018 Filed Jul 6, 2018 20:29 UTC |
Blackley SethDirector · President
|
SaleClass A Common Stock | 32,643 | $22.51 | $734,793.93 |
DisclosureSEC source: 0001628908-18-000057 · primary_doc.xml · nonDerivative · entry 6 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,837 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F7 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $22.250-$22.775, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 05, 2018 Filed Jul 6, 2018 20:29 UTC |
Blackley SethDirector · President
|
Exercise / conversionClass A Common Stock | 32,643 | $3.84 | $125,349.12 |
DisclosureSEC source: 0001628908-18-000057 · primary_doc.xml · nonDerivative · entry 5 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 05, 2018 Filed Jul 6, 2018 20:29 UTC |
Blackley SethDirector · President
|
SaleClass A Common Stock | 33,467 | $22.52 | $753,676.84 |
DisclosureSEC source: 0001628908-18-000057 · primary_doc.xml · nonDerivative · entry 4 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,837 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F6 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $22.250-$22.775, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 03, 2018 Filed Jul 6, 2018 20:29 UTC |
Blackley SethDirector · President
|
Exercise / conversionClass A Common Option (Right to Buy) · Derivative | 48,930 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-18-000057 · primary_doc.xml · derivative · entry 7 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,237 Underlying: Class A Common Stock · 48,930 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F5 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014. Read SEC document |
| July 03, 2018 Filed Jul 6, 2018 20:29 UTC |
Blackley SethDirector · President
|
SaleClass A Common Stock | 48,930 | $22.16 | $1,084,288.80 |
DisclosureSEC source: 0001628908-18-000057 · primary_doc.xml · nonDerivative · entry 3 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,304 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F4 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $21.60-$22.60, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 03, 2018 Filed Jul 6, 2018 20:29 UTC |
Blackley SethDirector · President
|
Exercise / conversionClass A Common Stock | 48,930 | $3.84 | $187,891.20 |
DisclosureSEC source: 0001628908-18-000057 · primary_doc.xml · nonDerivative · entry 2 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 03, 2018 Filed Jul 6, 2018 20:29 UTC |
Blackley SethDirector · President
|
SaleClass A Common Stock | 49,099 | $22.16 | $1,088,033.84 |
DisclosureSEC source: 0001628908-18-000057 · primary_doc.xml · nonDerivative · entry 1 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,304 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $21.60-$22.60, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 16:22 UTC |
WILLIAMS FRANK JDirector · Chief Executive Officer
|
SaleClass A Common Stock | 10,231 | $21.22 | $217,101.82 |
DisclosureSEC source: 0001628908-18-000054 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,812 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $20.600-$21.575, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 21:07 UTC |
Blackley SethDirector · President
|
Exercise / conversionClass A Common Option (right to buy) · Derivative | 41,873 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-18-000056 · primary_doc.xml · derivative · entry 4 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,167 Underlying: Class A Common Stock · 41,873 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F5 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 21:07 UTC |
Blackley SethDirector · President
|
SaleClass A Common Stock | 41,873 | $21.22 | $888,545.06 |
DisclosureSEC source: 0001628908-18-000056 · primary_doc.xml · nonDerivative · entry 3 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,403 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F4 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $20.65-$21.60, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 21:07 UTC |
Blackley SethDirector · President
|
Exercise / conversionClass A Common Stock | 41,873 | $3.84 | $160,792.32 |
DisclosureSEC source: 0001628908-18-000056 · primary_doc.xml · nonDerivative · entry 2 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 21:07 UTC |
Blackley SethDirector · President
|
SaleClass A Common Stock | 41,824 | $21.21 | $887,087.04 |
DisclosureSEC source: 0001628908-18-000056 · primary_doc.xml · nonDerivative · entry 1 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,403 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $20.65-$21.60, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:38 UTC |
Peterson Thomas IIIChief Operating Officer
|
SaleClass A Common Stock | 10,000 | $21.21 | $212,100.00 |
DisclosureSEC source: 0001628908-18-000055 · primary_doc.xml · nonDerivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,868 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is as weighted average. These shares were sold in multiple transactions at prices ranging from $20.60-$21.55, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 18:08 UTC |
WILLIAMS FRANK JDirector · Chief Executive Officer
|
SaleClass A Common Stock | 47,314 | $24.00 | $1,135,536.00 |
DisclosureSEC source: 0001628908-18-000053 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 821,043 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 20:31 UTC |
Blackley SethDirector · President
|
SaleClass A Common Stock | 16,674 | $23.33 | $389,004.42 |
DisclosureSEC source: 0001628908-18-000052 · primary_doc.xml · nonDerivative · entry 1 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,227 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2017. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $23.20-$23.50, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 21:07 UTC |
Payson NormanDirector
|
GrantClass A Common Stock | 5,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-18-000047 · primary_doc.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,284 F1 · security: Represents restricted stock units granted to Dr. Payson pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 13, 2019 and the date of the company's 2019 annual meeting, subject to the reporting person's continued service on the vesting date. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:17 UTC |
D'Amato MichaelDirector
|
GrantClass A Common Stock | 5,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-18-000042 · primary_doc.xml · nonDerivative · entry 1 D'Amato Michael · CIK 0001672282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,212 F1 · security: Represents restricted stock units granted to Mr. D'Amato pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 13, 2019 and the date of the company's 2019 annual meeting, subject to the reporting person's continued service on the vesting date. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 17:00 UTC |
Holder DianeDirector
|
GrantClass A Common Stock | 5,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-18-000046 · primary_doc.xml · nonDerivative · entry 1 Holder Diane · CIK 0001642976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,284 F1 · security: Represents restricted stock units granted to Ms. Holder pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 13, 2019 and the date of the company's 2019 annual meeting, subject to the reporting person's continued service on the vesting date. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:46 UTC |
Farner DavidDirector
|
GrantClass A Common Stock | 5,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-18-000044 · primary_doc.xml · nonDerivative · entry 1 Farner David · CIK 0001642786 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,284 F1 · security: Represents restricted stock units granted to Mr. Farner pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 13, 2019 and the date of the company's 2019 annual meeting, subject to the reporting person's continued service on the vesting date. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:53 UTC |
Felt Bruce C. Jr.Director
|
GrantClass A Common Stock | 5,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-18-000045 · primary_doc.xml · nonDerivative · entry 1 Felt Bruce C. Jr. · CIK 0001410700 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,284 F1 · security: Represents restricted stock units granted to Mr. Felt pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 13, 2019 and the date of the company's 2019 annual meeting, subject to the reporting person's continued service on the vesting date. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 21:15 UTC |
SAMET KENNETH ADirector
|
GrantClass A Common Stock | 5,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-18-000048 · primary_doc.xml · nonDerivative · entry 1 SAMET KENNETH A · CIK 0001359252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,879 F1 · security: Represents restricted stock units granted to Mr. Samet pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 13, 2019 and the date of the company's 2019 annual meeting, subject to the reporting person's continued service on the vesting date. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:38 UTC |
DUFFY MARY BRIDGETDirector
|
GrantClass A Common Stock | 5,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-18-000043 · primary_doc.xml · nonDerivative · entry 1 DUFFY MARY BRIDGET · CIK 0001570881 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,143 F1 · security: Represents restricted stock units granted to Dr. Duffy pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 13, 2019 and the date of the company's 2019 annual meeting, subject to the reporting person's continued service on the vesting date. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 21:21 UTC |
Scott CherylDirector
|
GrantClass A Common Stock | 5,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-18-000049 · primary_doc.xml · nonDerivative · entry 1 Scott Cheryl · CIK 0001656979 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,802 F1 · security: Represents restricted stock units granted to Ms. Scott pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 13, 2019 and the date of the company's 2019 annual meeting, subject to the reporting person's continued service on the vesting date. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 20:45 UTC |
Scott CherylDirector
|
SaleClass A Common Stock | 1,600 | $22.63 | $36,208.00 |
DisclosureSEC source: 0001628908-18-000039 · primary_doc.xml · nonDerivative · entry 1 Scott Cheryl · CIK 0001656979 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,343 F1 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $22.60-$22.675, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., and security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate prices within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 21:32 UTC |
Blackley SethDirector · President
|
SaleClass A Common Stock | 2,885 | $20.95 | $60,440.75 |
DisclosureSEC source: 0001628908-18-000038 · primary_doc.xml · nonDerivative · entry 2 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,901 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2017. F4 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $20.90-$21.00, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate prices within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 21:32 UTC |
Blackley SethDirector · President
|
SaleClass A Common Stock | 13,781 | $20.34 | $280,305.54 |
DisclosureSEC source: 0001628908-18-000038 · primary_doc.xml · nonDerivative · entry 1 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,786 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2017. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $19.85-$20.85, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 17:30 UTC |
WILLIAMS FRANK JDirector · Chief Executive Officer
|
SaleClass A Common Stock | 15,000 | $20.04 | $300,600.00 |
DisclosureSEC source: 0001628908-18-000036 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 868,357 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $19.65-$20.35, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 22:01 UTC |
Peterson Thomas IIIChief Operating Officer
|
SaleClass A Common Stock | 10,000 | $20.04 | $200,400.00 |
DisclosureSEC source: 0001628908-18-000037 · primary_doc.xml · nonDerivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,868 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $19.65-$20.40, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate prices within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 00:03 UTC |
UNITEDHEALTH GROUP INCDirector · Director by Deputization
|
SaleClass A Common Stock, par value $0.01 per share | 2,861,065 | $19.23 | $55,018,279.95 |
DisclosureSEC source: 0000899243-18-015033 · doc4.xml · nonDerivative · entry 1 UNITEDHEALTH GROUP INC · CIK 0000731766 · Director · Director by Deputization 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · ownership.direct: The Advisory Board Company, a Delaware corporation ("ABCO"), is the record and direct beneficial owner of the Class A Common Stock of Evolent Health, Inc. (including the Class A Common Stock issued upon the exchange of the Class B Units owned directly by ABCO). ABCO is a direct, wholly-owned subsidiary of OptumInsight, Inc., a Delaware corporation ("OptumInsight"), which is an indirect, wholly owned subsidiary of UnitedHealth Group Incorporated, a Delaware corporation ("UNH"). UNH and OptumInsight may be deemed to beneficially own the securities beneficially owned by ABCO. F1 · ownership.nature: The Advisory Board Company, a Delaware corporation ("ABCO"), is the record and direct beneficial owner of the Class A Common Stock of Evolent Health, Inc. (including the Class A Common Stock issued upon the exchange of the Class B Units owned directly by ABCO). ABCO is a direct, wholly-owned subsidiary of OptumInsight, Inc., a Delaware corporation ("OptumInsight"), which is an indirect, wholly owned subsidiary of UnitedHealth Group Incorporated, a Delaware corporation ("UNH"). UNH and OptumInsight may be deemed to beneficially own the securities beneficially owned by ABCO. Read SEC document |
| May 22, 2018 Filed May 24, 2018 20:50 UTC |
Weinberg JonathanGeneral Counsel
|
Exercise / conversionClass A Common Options (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-18-000035 · primary_doc.xml · derivative · entry 3 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,431 Underlying: Class A Common Stock · 15,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F4 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2016. Read SEC document |
| May 22, 2018 Filed May 24, 2018 20:50 UTC |
Weinberg JonathanGeneral Counsel
|
SaleClass A Common Stock | 15,000 | $20.02 | $300,300.00 |
DisclosureSEC source: 0001628908-18-000035 · primary_doc.xml · nonDerivative · entry 2 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,775 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F3 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $20.00-$20.05, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 22, 2018 Filed May 24, 2018 20:50 UTC |
Weinberg JonathanGeneral Counsel
|
Exercise / conversionClass A Common Stock | 15,000 | $3.84 | $57,600.00 |
DisclosureSEC source: 0001628908-18-000035 · primary_doc.xml · nonDerivative · entry 1 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 21, 2018 Filed May 23, 2018 20:40 UTC |
Blackley SethDirector · President
|
SaleClass A Common Stock | 16,666 | $19.39 | $323,153.74 |
DisclosureSEC source: 0001628908-18-000034 · primary_doc.xml · nonDerivative · entry 1 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,567 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2017. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $19.25-$19.55, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 14, 2018 Filed May 16, 2018 16:16 UTC |
WILLIAMS FRANK JDirector · Chief Executive Officer
|
SaleClass A Common Stock | 15,000 | $19.02 | $285,300.00 |
DisclosureSEC source: 0001628908-18-000032 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 883,357 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $19.00-$19.05, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 14, 2018 Filed May 16, 2018 20:31 UTC |
Peterson Thomas IIIChief Operating Officer
|
SaleClass A Common Stock | 10,000 | $18.91 | $189,100.00 |
DisclosureSEC source: 0001628908-18-000033 · primary_doc.xml · nonDerivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,868 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $18.65-$19.00, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 10, 2018 Filed May 11, 2018 20:48 UTC |
Blackley SethDirector · President
|
SaleClass A Common Stock | 64,398 | $17.63 | $1,135,336.74 |
DisclosureSEC source: 0001628908-18-000031 · primary_doc.xml · nonDerivative · entry 1 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,233 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2017. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $17.15-$18.35, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 08, 2018 Filed May 9, 2018 20:24 UTC |
Blackley SethDirector · President
|
SaleClass A Common Stock | 5,124 | $17.00 | $87,108.00 |
DisclosureSEC source: 0001628908-18-000026 · primary_doc.xml · nonDerivative · entry 2 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,631 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2017. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 07, 2018 Filed May 9, 2018 20:24 UTC |
Blackley SethDirector · President
|
SaleClass A Common Stock | 80,472 | $17.09 | $1,375,266.48 |
DisclosureSEC source: 0001628908-18-000026 · primary_doc.xml · nonDerivative · entry 1 Blackley Seth · CIK 0001643346 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,755 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2017. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $17.00-$17.30, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of share sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.